(via NewsDirect)
The procedure is used in life-threatening situations where a patient’s bioprosthetic aortic valve is failing due to calcification or structural deterioration, meaning a new heart valve must be implanted inside the failing valve. Paterson says the successful procedure further validates the company’s extensive pre-clinical valve-in-valve work as well as its clinical experience in native aortic stenosis.
Dr
“The unique design of DurAVR, including the low frame height and the single-piece design, makes the valve well-suited to address the needs of valve-in-valve patients,” she concluded.
Contact Details
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source